sorafenib has been researched along with panobinostat in 4 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (panobinostat) | Trials (panobinostat) | Recent Studies (post-2010) (panobinostat) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 678 | 95 | 593 |
| Protein | Taxonomy | sorafenib (IC50) | panobinostat (IC50) |
|---|---|---|---|
| Histone deacetylase 8 | Schistosoma mansoni | 0.45 | |
| Histone deacetylase 3 | Homo sapiens (human) | 0.2031 | |
| Bromodomain-containing protein 4 | Homo sapiens (human) | 0.005 | |
| Cytochrome P450 3A5 | Homo sapiens (human) | 0.0033 | |
| Histone deacetylase 4 | Homo sapiens (human) | 0.3792 | |
| Histone deacetylase 1 | Homo sapiens (human) | 0.181 | |
| Histone deacetylase 7 | Homo sapiens (human) | 0.9434 | |
| Histone deacetylase 2 | Homo sapiens (human) | 0.2527 | |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | 0.007 | |
| Histone deacetylase 11 | Homo sapiens (human) | 0.8396 | |
| Histone deacetylase 8 | Homo sapiens (human) | 0.46 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.2307 | |
| Histone deacetylase 9 | Homo sapiens (human) | 0.5825 | |
| Histone deacetylase 5 | Homo sapiens (human) | 0.3424 | |
| Histone deacetylase | Plasmodium falciparum (malaria parasite P. falciparum) | 0.0025 | |
| Nuclear receptor corepressor 2 | Homo sapiens (human) | 0.002 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, D; Goh, WH; Soh, CK; Wang, H | 1 |
| Alsinet, C; Cabellos, L; Friedman, SL; Hoshida, Y; Lachenmayer, A; Llovet, JM; Minguez, B; Thung, S; Toffanin, S; Tsai, HW; Villanueva, A; Ward, SC | 1 |
| Goertz, RS; Knieling, F; Strobel, D; Waldner, MJ | 1 |
| Bartsch, DK; Di Fazio, P; Holzer, K; Keber, C; Knauff, F; Manoharan, J; Maurer, E; Roth, S; Wächter, S | 1 |
4 other study(ies) available for sorafenib and panobinostat
| Article | Year |
|---|---|
Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Screening Assays, Antitumor; Heterografts; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Liver Neoplasms; Liver Neoplasms, Experimental; Mice; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2018 |
Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.
Topics: Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Benzenesulfonates; Cadherins; Carcinoma, Hepatocellular; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Niacinamide; Panobinostat; Phenylurea Compounds; Polymorphism, Single Nucleotide; Pyridines; RNA, Messenger; Sorafenib; Survivin; Xenograft Model Antitumor Assays | 2012 |
Quantification of dynamic contrast-enhanced ultrasound in HCC: prediction of response to a new combination therapy of sorafenib and panobinostat in advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Contrast Media; Fatal Outcome; Humans; Hydroxamic Acids; Indoles; Liver Neoplasms; Male; Neoplasm Staging; Niacinamide; Panobinostat; Phenylurea Compounds; Sorafenib; Ultrasonography | 2012 |
Synergic Induction of Autophagic Cell Death in Anaplastic Thyroid Carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Autophagy; Cell Death; Cell Line, Tumor; Humans; Male; Panobinostat; Sorafenib; Spheroids, Cellular; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms | 2023 |